1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
2. Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with lower gastrointestinal or pancreatic cancer and his or her caregiver.
3. Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lower GI or pancreatic cancers.
4. Select relevant information and guidance for the public regarding lower gastrointestinal and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
5. Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower gastrointestinal or pancreatic cancers, including chemotherapy-induced diarrhea, hand-foot syndrome, hand foot skin reaction, neurotoxicity from oxaliplatin, management of hypersensitivity reactions to monoclonal antibodies used for solid tumors, and dermatologic toxicities from epidermal growth factor receptor inhibitors.